Latest news with #MarkMassaro
Yahoo
04-05-2025
- Business
- Yahoo
Why Investors Were Avoiding GeneDx Holdings Stock This Week
The company crushed analyst estimates in its first quarter, but for many investors it didn't crush them enough. Regardless, several analysts cut their price targets just after the earnings release was published. With a nearly 39% stock price decline this week, according to data compiled by S&P Global Market Intelligence, GeneDx Holdings (NASDAQ: WGS) was deep in the doghouse with investors. They traded out of the stock following the company's latest earnings release and a subsequent round of analyst price target cuts. What's interesting about GeneDx's tumble is that its first-quarter performance was, on the surface, rather good. The figures released Wednesday revealed the DNA testing company managed to boost its revenue by 42% on a year-over-year basis to slightly more than $87 million. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » On the bottom line, it posted non-GAAP (adjusted) net income of nearly $7.7 million ($0.27 per share) against the year-ago loss of nearly $8 million. Both numbers well exceeded the consensus analyst estimates. The catch was that GeneDx has posted more spectacular beats on analyst estimates in the past, to the point where many market players are expecting a continued level of outperformance -- and disappointed when they don't get it. Adding to the generally bearish sentiment, several pundits tracking GeneDx stock trimmed their price targets on the stock. One of the cutters was BTIG's Mark Massaro, who now feels the company is fairly valued at $100 per share; previously his level was $115. According to reports Massaro's modeling indicates that the company now trades at only 4 times his 2026 revenue estimate, making it attractively cheap on that basis. This is a key reason why he maintained his buy recommendation despite the price target cut. The BTIG pundit wrote in his analysis that investors overreacted to GeneDx's quarterly results, and I'd agree. I think this is one of the more solid businesses in the biotech world, and I don't feel investors should bail on it if it doesn't meet inflated growth expectations. Before you buy stock in GeneDx, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and GeneDx wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $611,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $684,068!* Now, it's worth noting Stock Advisor's total average return is 889% — a market-crushing outperformance compared to 162% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 28, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Investors Were Avoiding GeneDx Holdings Stock This Week was originally published by The Motley Fool
Yahoo
21-04-2025
- Business
- Yahoo
Tempus AI Gets Bullish Boost from BTIG on Data Strength, Expansion Moves
BTIG just kicked off coverage on Tempus AI (NASDAQ:TEM) with a Buy rating and a $60 price target suggesting nearly 48% upside from where the stock trades now. Analyst Mark Massaro called the company's AI-driven data operations a significant free call option for investors, pointing to its potential for long-term growth. Warning! GuruFocus has detected 3 Warning Signs with TEM. Massaro described Tempus as a fast-growing tech company in the precision medicine space. It's starting with oncology but has already begun branching out into other areas. He also noted that the company is off to a solid start in monetizing its genomics and data services through work with pharmaceutical companies and cancer specialists. One big advantage? Tempus has one of the largest molecular libraries of cancer data. That puts it in a strong position to lead the charge in AI-powered healthcare analytics. The company's also building momentum through key partnerships. It recently teamed up with Illumina (NASDAQ:ILMN) to use AI in genomics research, expanding its focus to heart and brain conditions. On top of that, it struck a long-term deal with Recursion Pharmaceuticals (NASDAQ:RXRX) to support cancer drug development using Tempus' biomarker data. BTIG sees these moves as expanding Tempus' role in precision medicine and opening up new growth markets. And while the stock has seen a bit of turbulence lately down 1.09% over the past week it's actually held up better than the S&P 500, which dropped 2.65% in the same period. Over the past month and six months, Tempus is down 20.09% and 17.00%, respectively, but again has outperformed the S&P's declines of 9.63% and 12.21%. So far this year, Tempus is up 18.04%, compared to a 12.81% drop in the broader index a sign of strength even amid recent volatility. This article first appeared on GuruFocus.
